This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients (iWITH)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Immune Tolerance Network (ITN)
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT01638559
First received: July 9, 2012
Last updated: May 19, 2017
Last verified: May 2017
July 9, 2012
May 19, 2017
August 2012
March 2016   (Final data collection date for primary outcome measure)
Number of Operationally Tolerant Participants [ Time Frame: 12 Months after Complete immunosuppression withdrawal ]
The number of participants that are operationally tolerant, defined as those who successfully withdraw from immunosuppression and maintain normal allograft status as assessed by liver biopsy and liver tests 12 months after complete immunosuppression withdrawal.
Proportion of subjects with normal liver biopsy and test results [ Time Frame: 12 months post-IS withdrawal ]
The proportion of participants that is operationally tolerant, defined as those who successfully withdraw from IS and maintain normal allograft status as assessed by liver biopsy and liver tests 12 months after complete ISW.
Complete list of historical versions of study NCT01638559 on ClinicalTrials.gov Archive Site
Not Provided
  • Composite of refractory acute rejection (AR), chronic rejection (CR), requirement for retransplantation, or death [ Time Frame: 48 months ]
    Rate of a composite outcome measure defined as the proportion of participants who develop refractory AR, chronic rejection (CR), undergo retransplantation,or die during study participation.
  • Histologic severity of AR episodes according to Banff criteria [ Time Frame: 48 months ]
  • Clinical severity of AR episodes assessed by treatment and time necessary to resolve AR or allograft dysfunction [ Time Frame: 48 months ]
  • Histologic progression determined from the stage of fibrosis at baseline to completion of the study according to the Ishak Severity System [ Time Frame: 48 months ]
  • Durability of operational tolerance defined as the time from achievement of the primary endpoint to IS reinitiation or to the end of trial participation [ Time Frame: 48 months ]
  • Percent of IS dose reduction achieved prior to failing the primary endpoint for any reason [ Time Frame: 24 months ]
  • Percent of IS dose reduction in IS dose for those who fail to achieve the primary endpoint [ Time Frame: 24 months ]
Not Provided
Not Provided
 
Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients
Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients
The primary objective of this study is to assess the efficacy of immunosuppression withdrawal (ISW) in pediatric liver transplant (tx) recipients.

Anti-rejection medicines, also known as immunosuppressive drugs, are prescribed to organ transplant recipients to prevent rejection of the new organ. Long-term use of these medicines places transplant recipients at higher risk of serious infections and certain types of cancer.

This study seeks to:

  • Find out if it is safe to slowly reduce and then completely stop the immunosuppression taken by children who have received liver transplants. This process is called 'immunosuppression withdrawal'or ISW.
  • Find blood or liver biopsy tests that can help transplant doctors in the future to predict if it is safe to decrease or stop immunosuppression drugs in children who have had a liver transplant.
Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
  • Liver Transplant Recipients
  • Liver Transplantation
  • Immunosuppression
Drug: Immunosuppression withdrawal
Participants will undergo gradual ISW in no less than 36 weeks and no more than 52 weeks with frequent monitoring of liver tests. All participants will be followed for 48 months ensuring a minimum of 36 months of follow-up after successful ISW.
Other Name: ISW
Experimental: Immunosuppression withdrawal
Gradual withdrawal of immunosuppressive treatment withdrawal as per protocol.
Intervention: Drug: Immunosuppression withdrawal

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
88
May 28, 2018
March 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subject and/or parent guardian must be able to understand and provide informed consent;
  • Is the recipient of a living or deceased donor liver tx when subject was less than or equal to 6 years of age;
  • Is at least 4 years post-tx at the time of study enrollment;
  • Has normal allograft function defined as Alanine aminotransferase (ALT) < 50 IU/l and gamma-glutamyl transferase (GGT) < 50 IU/l;
  • Has no evidence of acute rejection (AR) or chronic rejection (CR) within the past 2 years, based on medical history;
  • Is stable on IS monotherapy with a calcineurin inhibitor (CNI);
  • For female subjects of childbearing potential, subject must have a negative pregnancy test upon study entry;
  • For female and male subjects with reproductive potential, subject must agree to use FDA approved methods of birth control for the duration of the study;
  • Must be negative for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection within one year of enrollment;
  • Must have screening biopsy that fulfills, based on central pathology reading, the following criteria:

    • Portal inflammation and interface activity: Preferably absent, but minimal to focal mild portal mononuclear inflammation may be present. Interface necro-inflammatory activity is absent or equivocal/minimal and, if present, involves a minority of portal tracts.
    • Centrizonal/peri-venular inflammation: Preferably absent, but minimal to focal mild perivenular mononuclear inflammation may be present. Perivenular necro-inflammatory activity is absent or equivocal/minimal and, if present, involves a minority of terminal hepatic venules.
    • Bile duct changes: No lymphocytic bile duct damage, ductopenia and biliary epithelial senescence changes, unless there is an alternative, non-immunologic explanation (e.g. biliary strictures).
    • Fibrosis: < Ishak Stage 3 (i.e. not more than occasional portal-to-portal bridging). Perivenular fibrosis should be less than "moderate", according to Banff Criteria.
    • Arteries: Negative for obliterative or foam cell arteriopathy.

Exclusion Criteria:

  • Have received a liver tx for autoimmune liver disease, including autoimmune hepatitis or primary sclerosing cholangitis;
  • Have received a liver tx for hepatitis B or hepatitis C;
  • Have received a second organ transplant before, simultaneously, or after liver tx;
  • Have a calculated glomerular filtration rate (modified Schwartz formula) of less than 60 mL/min/1.73 m^2;
  • Have had a 50 percent (%) dose increase in CNI within 6 months of screening;
  • Have discontinued a second IS agent within 12 months of screening;
  • Have any systemic illness requiring or likely to require chronic or recurrent use of IS;
  • Is pregnant or breastfeeding;
  • Is unwilling or unable to adhere with study requirements and procedures;
  • Have mental illness or history of drug or alcohol abuse that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements;
  • Is unwilling or unable to provide consent or comply with the study protocol;
  • Has used investigational drugs within 4 weeks of enrollment;
  • Is receiving treatment for HIV infection;
  • Has received any licensed or investigational live attenuated vaccine(s) within two months of enrollment;
  • Has any medical condition that, in the opinion of the investigator, will interfere with safe participation in the trial.
Sexes Eligible for Study: All
up to 18 Years   (Child, Adult)
No
Contact information is only displayed when the study is recruiting subjects
Canada,   United States
 
 
NCT01638559
DAIT iWITH
5U01AI100807-04 ( US NIH Grant/Contract Award Number )
RTB-001 ( Other Identifier: DAIT NIAID )
Yes
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Yes
The plan, upon completion of the study, is to share data in ImmPort [https://immport.niaid.nih.gov/ ], a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • Immune Tolerance Network (ITN)
Principal Investigator: S Feng, M.D. , Ph.D. University of California, San Francisco
Study Chair: J Bucuvalas, M.D. Children's Hospital Medical Center, Cincinnati
National Institute of Allergy and Infectious Diseases (NIAID)
May 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP